Cargando…

Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients

BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolinger, Guilherme D., Vállez García, David, Kramer, Gerbrand M., Frings, Virginie, Smit, Egbert F., de Langen, Adrianus J., Dierckx, Rudi A. J. O., Hoekstra, Otto S., Boellaard, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367490/
https://www.ncbi.nlm.nih.gov/pubmed/30734113
http://dx.doi.org/10.1186/s13550-019-0481-1
_version_ 1783393811052888064
author Kolinger, Guilherme D.
Vállez García, David
Kramer, Gerbrand M.
Frings, Virginie
Smit, Egbert F.
de Langen, Adrianus J.
Dierckx, Rudi A. J. O.
Hoekstra, Otto S.
Boellaard, Ronald
author_facet Kolinger, Guilherme D.
Vállez García, David
Kramer, Gerbrand M.
Frings, Virginie
Smit, Egbert F.
de Langen, Adrianus J.
Dierckx, Rudi A. J. O.
Hoekstra, Otto S.
Boellaard, Ronald
author_sort Kolinger, Guilherme D.
collection PubMed
description BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i.e. intersection between two or more delineations (MV2) and between three or more delineations (MV3). To evaluate the accuracy of those methods, they were compared with a reference delineation obtained from the consensus of the segmentations performed by three experienced observers. Ten NSCLC patients underwent two baseline whole-body [(18)F]2-Fluoro-2-deoxy-2-D-glucose ([(18)F]FDG) PET/CT studies on separate days, within 3 days. Two scans were obtained on each day at 60 and 90 min post-injection to assess the influence of tracer uptake interval. PET/CT images were reconstructed following the European Association of Nuclear Medicine Research Ltd. (EARL) compliant settings and with point-spread-function (PSF) modelling. Repeatability between the measurements of each day was determined and the influence of uptake interval, reconstruction settings, and lesion delineation method was assessed using the generalized estimating equations model. RESULTS: Based on the Jaccard index with the reference delineation, the MV2 lesion delineation method was the most successful method for automated lesion segmentation. The best overall repeatability (lowest repeatability coefficient, RC) was found for TTB from 90 min of tracer uptake scans reconstructed with EARL compliant settings and delineated with 41% of lesion’s maximum SUV method (RC = 11%). In most cases, TMATV and TTB repeatability were not significantly affected by changes in tracer uptake time or reconstruction settings. However, some lesion delineation methods had significantly different repeatability when applied to the same images. CONCLUSIONS: This study suggests that under some circumstances TMATV and TTB repeatability are significantly affected by the lesion delineation method used. Performing the delineation with a majority vote approach improves reliability and does not hamper repeatability, regardless of acquisition and reconstruction settings. It is therefore concluded that by using a majority vote based tumour segmentation approach, TMATV and TTB in NSCLC patients can be measured with high reliability and precision. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13550-019-0481-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6367490
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-63674902019-02-28 Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients Kolinger, Guilherme D. Vállez García, David Kramer, Gerbrand M. Frings, Virginie Smit, Egbert F. de Langen, Adrianus J. Dierckx, Rudi A. J. O. Hoekstra, Otto S. Boellaard, Ronald EJNMMI Res Original Research BACKGROUND: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i.e. intersection between two or more delineations (MV2) and between three or more delineations (MV3). To evaluate the accuracy of those methods, they were compared with a reference delineation obtained from the consensus of the segmentations performed by three experienced observers. Ten NSCLC patients underwent two baseline whole-body [(18)F]2-Fluoro-2-deoxy-2-D-glucose ([(18)F]FDG) PET/CT studies on separate days, within 3 days. Two scans were obtained on each day at 60 and 90 min post-injection to assess the influence of tracer uptake interval. PET/CT images were reconstructed following the European Association of Nuclear Medicine Research Ltd. (EARL) compliant settings and with point-spread-function (PSF) modelling. Repeatability between the measurements of each day was determined and the influence of uptake interval, reconstruction settings, and lesion delineation method was assessed using the generalized estimating equations model. RESULTS: Based on the Jaccard index with the reference delineation, the MV2 lesion delineation method was the most successful method for automated lesion segmentation. The best overall repeatability (lowest repeatability coefficient, RC) was found for TTB from 90 min of tracer uptake scans reconstructed with EARL compliant settings and delineated with 41% of lesion’s maximum SUV method (RC = 11%). In most cases, TMATV and TTB repeatability were not significantly affected by changes in tracer uptake time or reconstruction settings. However, some lesion delineation methods had significantly different repeatability when applied to the same images. CONCLUSIONS: This study suggests that under some circumstances TMATV and TTB repeatability are significantly affected by the lesion delineation method used. Performing the delineation with a majority vote approach improves reliability and does not hamper repeatability, regardless of acquisition and reconstruction settings. It is therefore concluded that by using a majority vote based tumour segmentation approach, TMATV and TTB in NSCLC patients can be measured with high reliability and precision. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13550-019-0481-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-02-07 /pmc/articles/PMC6367490/ /pubmed/30734113 http://dx.doi.org/10.1186/s13550-019-0481-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Kolinger, Guilherme D.
Vállez García, David
Kramer, Gerbrand M.
Frings, Virginie
Smit, Egbert F.
de Langen, Adrianus J.
Dierckx, Rudi A. J. O.
Hoekstra, Otto S.
Boellaard, Ronald
Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title_full Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title_fullStr Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title_full_unstemmed Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title_short Repeatability of [(18)F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients
title_sort repeatability of [(18)f]fdg pet/ct total metabolic active tumour volume and total tumour burden in nsclc patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367490/
https://www.ncbi.nlm.nih.gov/pubmed/30734113
http://dx.doi.org/10.1186/s13550-019-0481-1
work_keys_str_mv AT kolingerguilhermed repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT vallezgarciadavid repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT kramergerbrandm repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT fringsvirginie repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT smitegbertf repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT delangenadrianusj repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT dierckxrudiajo repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT hoekstraottos repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients
AT boellaardronald repeatabilityof18ffdgpetcttotalmetabolicactivetumourvolumeandtotaltumourburdeninnsclcpatients